A world-leading capability that supports customers from discovery through to clinical development.
Drug developers face numerous challenges when bridging from drug discovery into pre-clinical and clinical development.
Traditionally, the pharmaceutical industry has been structured around different functional disciplines, requiring sponsors to split their drug development programs across multiple service providers. This limits knowledge and material sharing, while ultimately adding time and cost to development.
Charles River and Arcinova, A Quotient Sciences Company, have formed a collaboration to address these challenges. Combining expertise of both companies, we can bridge molecules from early discovery to proof of concept (POC) and beyond.
Image
Deep scientific expertise in drug development
Flexible programmes that match the needs of your molecule
Dedicated project teams throughout development
Customised pathways to clinical development
Charles River Expertise:
- Support from early discovery through to IND/CTA submission
- Medicinal chemistry, in-vitro and in-vivo biology, drug metabolism and pharmacokinetics (DMPK), early pharmaceutics, and non-clinical safety services
- Teams have collectively worked on over 80% of FDA-approved drugs in the last 3 years alone
Arcinova Expertise:
- Support from lead candidate selection through to Phase II
- Over 40 year history of drug substance synthesis and manufacturing services including bioanalysis
- Drug product design and development, including clinical trial manufacturing services